Pharmac Widening Access To A Treatment For People With A Rare Blood Cancer

People in New Zealand living with a type of blood cancer, systemic anaplastic large cell lymphoma (sALCL), will benefit from wider access to the medicine brentuximab vedotin, from 1 April 2026.

This change comes after Pharmac consulted on a proposal for brentuximab vedotin to be used as a first-line treatment option in people newly diagnosed with sALCL.

“This will mean people could receive brentuximab vedotin as a first treatment option, instead of waiting until other options have been tried,” says Pharmac’s Manager of Pharmaceutical Funding, Claire Pouwels. “Around 12 people are expected to benefit in the first year, with around 60 people benefitting over the next 5 years.”

Brentuximab vedotin is currently funded only for people whose lymphoma has returned or has not responded to earlier treatment. Using brentuximab vedotin earlier is expected to support better outcomes for people with sALCL, who often face poor survival rates and significant health needs.

“Systemic anaplastic large cell lymphoma is rare form of cancer that is often diagnosed in people under 55,” says Pouwels. “Making this treatment available earlier has the potential to improve both survival and quality of life.”

© Scoop Media